In Treatment of Angina (heart-related chest pain) Millisrol 5mg Injection helps in prevention as well as treatment of angina. Angina is a chest pain that is usually caused by narrowing of the blood vessels which supply your heart. This means your heart does not get enough oxygen. Millisrol 5mg Injection works quickly to relax the muscles and blood vessels in your heart so more blood (and oxygen) gets to your heart. This reduces the pain and discomfort that angina causes. You should take this medicine at the first sign of chest pain. If the first tablet does not work, you can take a second tablet after 5 minutes. However, if your chest pain does not go away after 15 minutes, you should get urgent medical attention. This could be a sign of a heart attack. Millisrol 5mg Injection also helps prevent chest pain if taken before exercising or doing other strenuous activities.
Consuming alcohol while taking Millisrol 5mg Injection may cause symptoms such as flushing, increased heart beat, nausea, thirst, chest pain and low blood pressure (Disulfiram reaction).
Millisrol 5mg Injection is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Millisrol 5mg Injection is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Millisrol 5mg Injection may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Millisrol 5mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Millisrol 5mg Injection may not be needed in these patients. Please consult your doctor.
There is limited information available on the use of Millisrol 5mg Injection in patients with liver disease. Please consult your doctor.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Troikaa Pharmaceuticals Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Criticare Laboratories Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Swiss Pharma Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Fulford India Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Neon Laboratories Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Shree Ganesh Pharmaceuticals || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Troikaa Pharmaceuticals Ltd || ₹14.5/tablet (25% cheaper)